News >

Biomarker Analysis Identifies Prognostic Markers for Aflibercept Efficacy in CRC

Virginia Powers, PhD
Published: Thursday, Jul 06, 2017

Sabine Tejpar, MD, PhD

Sabine Tejpar, MD, PhD

Ziv-aflibercept (Zaltrap) prolonged overall survival (OS) compared to placebo across subgroups of patients with metastatic colorectal cancer (mCRC) with wild-type and mutated RAS, KRAS, and BRAF genes; in addition, this efficacy was unaffected by right-sided versus left-sided location of the primary tumor, according to findings presented at the 2017 ESMO World Congress on Gastrointestinal Cancer (WGI).

“These data provide more granular evidence for treatment options within the guidelines,” commented Tejpar. “Our assessment is ongoing, and the discovery of predictive biomarkers that associate with aflibercept efficacy will aid patient selection and treatment decisions.”
Wirapati P, Pomella C, Vandenbosch B, et al. VELOUR trial biomarkers update: impact of RAS, BRAF, and sidedness on aflibercept activity. [ESMO WGI Abstract LBA-005]. Ann Oncol. 2017;28(suppl_3).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication